ES2190570T3 - Compuestos heterociclicos de piperazinilo para el tratamiento de la demencia. - Google Patents

Compuestos heterociclicos de piperazinilo para el tratamiento de la demencia.

Info

Publication number
ES2190570T3
ES2190570T3 ES98310295T ES98310295T ES2190570T3 ES 2190570 T3 ES2190570 T3 ES 2190570T3 ES 98310295 T ES98310295 T ES 98310295T ES 98310295 T ES98310295 T ES 98310295T ES 2190570 T3 ES2190570 T3 ES 2190570T3
Authority
ES
Spain
Prior art keywords
dysfunctions
chlorine
fluorine
optionally substituted
benzoxazolilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98310295T
Other languages
English (en)
Inventor
Eric Jacob Watsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2190570T3 publication Critical patent/ES2190570T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)

Abstract

SE PRESENTA EL USO DE UN COMPUESTO DE LA FORMULA (I) EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES O DISFUNCIONES PSIQUIATRICAS SELECCIONADAS ENTRE LA DEMENCIA, LA DEMENCIA DEL TIPO ALZHEIMER, DISFUNCIONES DE LA ANSIEDAD, EPISODIOS PSICOTICOS DE LA ANSIEDAD, LA ANSIEDAD ASOCIADA CON LA PSICOSIS, LAS DISFUNCIONES DEL ANIMO ASOCIADAS CON DISFUNCIONES PSICOTICAS, LAS DISFUNCIONES PSICOTICAS DEL ANIMO, LAS DISFUNCIONES DEL ANIMO ASOCIADOS CON AL ESQUIZOFRENIA, LAS DISNESIAS Y LAS MANIFESTACIONES DEL COMPORTAMIENTO DEL RETRASO MENTAL, LAS DISFUNCIONES DE LA CONDUCTA Y LA ENFERMEDAD AUTISTA. SE PRESENTA UN COMPUESTO DE LA FORMULA (I) ASI COMO UNA SAL DE ADICION ACIDA FARMACOLOGICAMENTE ACEPTABLE DEL MISMO EN DONDE, AR ES BENZOISOTIAZOLILO O UN OXIDO O UN DIOXIDO DEL MISMO CADA UNO OPCIONALMENTE SUSTITUIDO POR FLUOR, CLORO, TRIFLUOROMETILO, METOXIDO, CIANO, NITRO O NAFTILO OPCIONALMENTE SUSTITUIDO POR FLUOR, CLORO, TRIFLUOROMETILO, METOXIDO, CIANO O NITRO; QUINOLILO; 6-HIDROXI-8-QUINOLILO; ISOQUINOLILO; QUINAZOLILO; BENZOTIAZOLILO; BENZOTIADIAZOLILO; BENZOXAZOLILO; BENZOTRIAZOLILO, BENZOXAZOLILO; BENZOXAZOLONILO, INDOILO; INDANILO OPCIONALMENTE SUSTITUIDO POR UNO O TRES FLUOR, 3INDAZOLILO OPCIONALMENTE SUSTITUIDO POR 1TRIFLUOROMETILOFENILO; O FTALACINILO; N ES 1 O 2; Y X E Y JUNTO CON EL FENILO AL CUAL ESTAN UNIDAS FORMAN QUINOLILO; 2-HIDROXIQUINOLILO; BENZOTIAZOLILO; 2AMINOBENZOTIAZOLILO; BENZOISOTIAZOLILO; INDAZOLILO; 2HIDROXIINDAZOLILO; INDOILO; ESPIRO, OXIDOLILO OPCIONALMENTE SUSTITUIDO POR ENTRE UNO Y TRES ALQUILO (C 1-3 ); O UNO DE CLORO, FLUOR O FENILO, EL FENILO OPCIONALMENTE SUSTITUIDO POR UNO DE CLORO O FLUOR; BENZOXAZOLILO; 2-AMINOBENZOXAZOLILO; BENZOXAZOLONILO; 2-AMINOBENZOXAZOLINILO; BENZOTIAZOLONILO; BENZOIMIDAZOLONILO; O BENZOTRIAZOLILO.
ES98310295T 1997-12-18 1998-12-15 Compuestos heterociclicos de piperazinilo para el tratamiento de la demencia. Expired - Lifetime ES2190570T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6806997P 1997-12-18 1997-12-18

Publications (1)

Publication Number Publication Date
ES2190570T3 true ES2190570T3 (es) 2003-08-01

Family

ID=22080230

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98310295T Expired - Lifetime ES2190570T3 (es) 1997-12-18 1998-12-15 Compuestos heterociclicos de piperazinilo para el tratamiento de la demencia.

Country Status (16)

Country Link
US (1) US6245766B1 (es)
EP (1) EP0931547B1 (es)
JP (1) JPH11246409A (es)
KR (1) KR19990066852A (es)
AT (1) ATE231394T1 (es)
AU (1) AU739472B2 (es)
CA (1) CA2256227C (es)
DE (1) DE69810889T2 (es)
DK (1) DK0931547T3 (es)
ES (1) ES2190570T3 (es)
HU (1) HUP9802958A1 (es)
IL (1) IL127497A (es)
MY (1) MY121036A (es)
NZ (1) NZ333436A (es)
TW (1) TW520989B (es)
ZA (1) ZA9811573B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
DK1408976T5 (da) 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
KR20050057404A (ko) * 2002-09-17 2005-06-16 워너-램버트 캄파니 엘엘씨 정신분열증 치료용 헤테로환 치환된 피페라진
MXPA05003658A (es) * 2002-10-28 2005-06-08 Warner Lambert Co Derivados de piperazina sustituidos con oxindol.
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
SI2316456T1 (sl) * 2003-04-29 2017-10-30 Orexigen Therapeutics, Inc. Sestavki za vplivanje na izgubo teže, ki obsegajo opioidni antagonist in bupropion
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
EP1633361A1 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Anxiety treatments with ziprasidone
BRPI0410222A (pt) * 2003-05-16 2006-05-09 Pfizer Prod Inc tratamento de distúrbios bipolares e sintomas associados
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
AR045362A1 (es) * 2003-08-18 2005-10-26 Solvay Pharm Bv Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona
AU2005206139B2 (en) * 2004-01-13 2009-02-26 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
AU2005215257A1 (en) * 2004-02-13 2005-09-01 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
WO2006055603A2 (en) * 2004-11-16 2006-05-26 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
MX2007013026A (es) * 2005-04-22 2008-01-11 Wyeth Corp Combinaciones terapeuticas para el tratamiento o prevencion de trastornos psicoticos.
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
BR112012016783A2 (pt) 2010-01-11 2015-09-01 Orexigen Therapeutics Inc "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
AU2013271622B2 (en) 2012-06-06 2018-03-01 Nalpropion Pharmaceuticals Llc Methods of treating overweight and obesity
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
MA41169A (fr) * 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0790236B1 (en) * 1996-02-13 2003-11-19 Pfizer Inc. Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DE69730902T2 (de) * 1996-05-07 2006-02-23 Pfizer Inc. Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
KR100333214B1 (ko) * 1996-05-07 2002-06-20 디. 제이. 우드, 스피겔 알렌 제이 5-(2-(4-(1,2-벤즈이소티아졸-3-일)-1-피페라지닐)에틸)-6-클로로-1,3-디하이드로-2(1에이치)인돌-2-온(지프라시돈)의메실레이트트리하이드레이트염,이의제조방법및도파민디2길항물질로서의이의용도
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal

Also Published As

Publication number Publication date
KR19990066852A (ko) 1999-08-16
DE69810889T2 (de) 2003-05-15
IL127497A0 (en) 1999-10-28
DE69810889D1 (de) 2003-02-27
HU9802958D0 (en) 1999-02-01
NZ333436A (en) 2000-06-23
TW520989B (en) 2003-02-21
ZA9811573B (en) 2000-06-19
ATE231394T1 (de) 2003-02-15
JPH11246409A (ja) 1999-09-14
AU9717098A (en) 1999-07-08
CA2256227C (en) 2003-07-01
AU739472B2 (en) 2001-10-11
CA2256227A1 (en) 1999-06-18
DK0931547T3 (da) 2003-02-24
HUP9802958A1 (hu) 2000-03-28
EP0931547A1 (en) 1999-07-28
US6245766B1 (en) 2001-06-12
EP0931547B1 (en) 2003-01-22
MY121036A (en) 2005-12-30
IL127497A (en) 2002-07-25

Similar Documents

Publication Publication Date Title
ES2190570T3 (es) Compuestos heterociclicos de piperazinilo para el tratamiento de la demencia.
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
ES2270142T3 (es) Aminociclohexano quinolinas y sus analogos azaisostericos con actividad antibacteriana.
AR047557A1 (es) Compuestos derivados de piridazina y su uso como agentes terapeuticos
ECSP099728A (es) Compuestos amino-heterocíclicos
JP2008509222A5 (es)
AR031248A1 (es) Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20011059A1 (es) Carboxamidas de pirimidina de formula (i) y composiciones que las comprenden
NO20021448L (no) Nye tiazolo-(4,5-D)pyrimidinforbindelser
ECSP045367A (es) "derivados de bencimidazol utiles como antagonistas de histamina h3"
BRPI0412348A (pt) derivados de piperazina e seu uso como agentes terapêuticos
ATE311380T1 (de) Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren
SE0400043D0 (sv) New compounds
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
AR050711A1 (es) Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central
ATE318266T1 (de) 3-substituierte chinolin-4- carbonsäureamidderivate als nk-3- und nk-2- rezeptorantagonisten
AR016644A1 (es) Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos
DE69420738D1 (de) Bicyclische heterocyclen als neurokinin a antagonisten
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE361306T1 (de) 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-(3.2.2 - nonanderivate, deren herstellung und deren therapeutische verwendung
AR031486A1 (es) Derivados de pirimidina
TR200400027T4 (tr) 5HT7 Alıcı Agonist Aktivitesine Sahip 4-(2-Piridil Piperazinler